AKT1 and hepatoblastoma: Luo et al. confirmed that canagliflozin reduces cell viability and migration in different HCC and hepatoblastoma lines, and this effect was associated with the reduced activation of the Akt pathway and reduced HIF-1α stabilization [112] (Figure 2).